Lansoprazole: a proton pump inhibitor

OBJECTIVE: To summarize the published data on lansoprazole, a proton pump inhibitor approved by the Food and Drug Administration for use in the treatment of duodenal ulcer, erosive esophagitis, and pathologic hypersecretory conditions (e.g., Zollinger-Ellison syndrome). DATA SOURCES: Published data on lansoprazole identified by MEDLINE searches (1985-1996), as well as other pertinent literature. STUDY SELECTION: Clinical efficacy trials discussed were limited to multicenter, double-blind, parallel group, prospective studies, where possible. DATA SYNTHESIS: Lansoprazole inhibits gastric acid secretion via inhibition of gastric hydrogen/potassium adenosine triphosphatase (H+,K(+)-ATPase), an enzyme of the gastric parietal cell membrane that forms part of the proton pump that performs the final step in the acid secretory process. Lansoprazole binds covalently to parietal cell H+,K(+)-ATPase, rendering it nonfunctional and inhibiting the secretion of gastric acid. In clinical trials, lansoprazole has been shown to be more effective than placebo and standard doses of histamine (H)2-receptor antagonists and as effective as standard doses of omeprazole for the treatment of peptic ulcer disease, gastroesophageal reflux, Zollinger-Ellison syndrome, and nonsteroidal antiinflammatory drug-induced lesions. CONCLUSIONS: Lansoprazole is safe and effective for the treatment of acid-related disorders. It is more effective than the H2-receptor antagonists and comparable to omeprazole for these indications. The choice between lansoprazole and omeprazole is likely to be institution-specific and pharmacoeconomic.

This article has been cited by other articles:

				K.-S. Yu, K.-S. Bae, J.-H. Shon, J.-Y. Cho, S.-Y. Yi, J.-Y. Chung, H.-S. Lim, I.-J. Jang, S.-G. Shin, K.-S. Song, et al. Pharmacokinetic and Pharmacodynamic Evaluation of a Novel Proton Pump Inhibitor, YH1885, in Healthy Volunteers J. Clin. Pharmacol., January 1, 2004; 44(1): 73 - 82. [Abstract] [Full Text] [PDF]

				K. Biswas, U. Bandyopadhyay, I. Chattopadhyay, A. Varadaraj, E. Ali, and R. K. Banerjee A Novel Antioxidant and Antiapoptotic Role of Omeprazole to Block Gastric Ulcer through Scavenging of Hydroxyl Radical J. Biol. Chem., March 21, 2003; 278(13): 10993 - 11001. [Abstract] [Full Text] [PDF]

				W. W. Nelson, L. C. Vermeulen, E. A. Geurkink, D. A. Ehlert, and M. Reichelderfer Clinical and Humanistic Outcomes in Patients With Gastroesophageal Reflux Disease Converted From Omeprazole to Lansoprazole Arch Intern Med, September 11, 2000; 160(16): 2491 - 2496. [Abstract] [Full Text]